• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Crude Oil Falls; Dick's Sporting Goods Earnings Miss Views

    8/22/23 3:07:13 PM ET
    $DFLI
    $DKS
    $FN
    $FRBK
    Industrial Machinery/Components
    Miscellaneous
    Other Specialty Stores
    Consumer Discretionary
    Get the next $DFLI alert in real time by email

    U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones falling over 100 points on Tuesday.

    The Dow traded down 0.39% to 34,330.87 while the NASDAQ rose 0.24% to 13,530.50. The S&P 500, also fell, dropping, 0.11% to 4,394.78.

    Check This Out: Top 5 Financial Stocks You May Want To Dump This Quarter

     

    Leading and Lagging Sectors

    Utilities shares rose by 0.3% on Tuesday.

    In trading on Tuesday, financial shares fell by 0.8%.

     

    Top Headline

    Dick's Sporting Goods, Inc. (NYSE:DKS) reported worse-than-expected second-quarter results and lowered FY23 guidance.

    Sales grew 3.6% Y/Y to $3.22 billion, missing the analyst consensus of $3.23 billion. Adjusted EPS of $2.82, down 23% Y/Y, missed the analyst consensus of $3.81.

    The company reduced the adjusted EPS outlook to $11.50-$12.30 from $12.90-$13.80 vs. the consensus of $13.49.

     

    Equities Trading UP

    Fulcrum Therapeutics, Inc. (NASDAQ:FULC) shares shot up 46% to $5.71 after the FDA lifted clinical hold on the company’s FTX-6058 for sickle cell disease.

    Shares of Fabrinet (NYSE:FN) got a boost, shooting 29% to $151.15 after the company reported better-than-expected fourth-quarter financial results and issued guidance.

    ProMIS Neurosciences, Inc. (NASDAQ:PMN) shares were also up, gaining 20% to $1.89. ProMIS Neurosciences announced a $20.4 million private placement financing at $1.88 per unit.

     

    Equities Trading DOWN

    Republic First Bancorp, Inc. (NASDAQ:FRBK) shares dropped 41% to $0.4132 after the Nasdaq notified the company that it will not be listed on the exchange because it has not filed its Form 10-K Annual Report with the SEC for FY22.

    Shares of DICK'S Sporting Goods, Inc. (NYSE:DKS) were down 24% to $112.21 after the company reported worse-than-expected second-quarter results and lowered FY23 guidance.

    Dragonfly Energy Holdings Corp. (NASDAQ:DFLI) was down, falling 17% to $1.5901 after the company reported downbeat second-quarter results and issued weak forecast for the third quarter.

    Also Check This Out: Hasbro To Rally Over 42%? Here Are 10 Other Analyst Forecasts For Tuesday

     

    Commodities

    In commodity news, oil traded down 0.6% to $80.25 while gold traded up 0.2% at $1,926.10.

    Silver traded up 0.6% to $23.48 on Tuesday while copper rose 1% to $3.7565.

     

    Euro zone

    European shares closed higher today. The eurozone’s STOXX 600 gained 0.68% London’s FTSE 100 rose 0.18% while Spain’s IBEX 35 Index climbed 0.55% The German DAX gained 0.66% French CAC 40 rose 0.59%, while Italy’s FTSE MIB Index jumped 0.64%.

    The Eurozone reported a current account surplus of EUR 36.8 billion in June versus a revised EUR 4.4 billion gap in the year-ago month. Italy's current account surplus widened to EUR 5.995 billion in June from EUR 0.938 billion in the year-ago month.

    Public sector net borrowing, excluding banks, in the UK increased to £4.3 billion in July from £0.9 billion in the year-ago month. The Confederation of British Industry survey's total order book balance fell by 6 points to a reading of -15 in August.

     

    Asia Pacific Markets

    Asian markets closed higher on Tuesday, with Japan’s Nikkei 225 rising 0.92%, China’s Shanghai Composite Index gaining 0.88% and Hong Kong’s Hang Seng Index gaining 0.95%. India’s S&P BSE Sensex, meanwhile, rose 0.01%.

     

    Economics

    Existing-home sales in the U.S. fell 2.2% from a month ago to an annualized rate of 4.07 million units in July.

    The Manufacturing Activity Index in the Richmond area rose to -7 in August compared to July’s reading of -9.

    Now Read This: Around $39M Bet On Energy Transfer? Check Out These 3 Stocks Insiders Are Buying

     

    COVID-19 Update

    The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 107,846,210 cases with around 1,172,800 deaths. India confirmed a total of at least 44,996,650 cases and 531,920 deaths, while France reported over 40,138,560 COVID-19 cases with 167,640 deaths. In total, there were at least 694,026,200 cases of COVID-19 worldwide with more than 6,909,370 deaths.

     

    Get the next $DFLI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DFLI
    $DKS
    $FN
    $FRBK

    CompanyDatePrice TargetRatingAnalyst
    Fabrinet
    $FN
    2/4/2026$540.00Peer Perform → Outperform
    Wolfe Research
    Fabrinet
    $FN
    1/14/2026$537.00Equal Weight → Overweight
    Barclays
    Fulcrum Therapeutics Inc.
    $FULC
    1/12/2026$20.00Overweight
    Analyst
    Fabrinet
    $FN
    12/15/2025$550.00Positive
    Susquehanna
    Dick's Sporting Goods Inc
    $DKS
    11/26/2025$255.00 → $245.00Outperform
    Telsey Advisory Group
    Fulcrum Therapeutics Inc.
    $FULC
    11/24/2025Buy
    Truist
    Dick's Sporting Goods Inc
    $DKS
    9/26/2025$177.00Underperform
    BNP Paribas Exane
    Dick's Sporting Goods Inc
    $DKS
    9/23/2025$274.00Buy
    Goldman
    More analyst ratings

    $DFLI
    $DKS
    $FN
    $FRBK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Fabrinet upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded Fabrinet from Peer Perform to Outperform and set a new price target of $540.00

    2/4/26 8:55:11 AM ET
    $FN
    Telecommunications Equipment
    Utilities

    Fabrinet upgraded by Barclays with a new price target

    Barclays upgraded Fabrinet from Equal Weight to Overweight and set a new price target of $537.00

    1/14/26 8:21:25 AM ET
    $FN
    Telecommunications Equipment
    Utilities

    Analyst initiated coverage on Fulcrum Therapeutics with a new price target

    Analyst initiated coverage of Fulcrum Therapeutics with a rating of Overweight and set a new price target of $20.00

    1/12/26 8:13:43 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DFLI
    $DKS
    $FN
    $FRBK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

    CAMBRIDGE, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, will host a conference call and webcast on Tuesday, February 24, 2026 beginning at 8:00 a.m. ET to present 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease. Members of Fulcrum management will be joined by Dr. Martin Steinberg, Professor of Medicine, Pediatrics, Pathology and Laboratory Medicine at Boston University Chobanian and Avedisian School of Medicine. To register for

    2/17/26 8:00:00 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to one new employee. Fulcrum granted stock options to purchase shares of the company's common stock pursuant to the company's 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employee entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4). Fulcrum granted the new employee 70,000 options to purc

    2/6/26 4:30:00 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DICK'S Sporting Goods, Inc. Fourth Quarter Results Call Scheduled for March 12th

    PITTSBURGH, Feb. 6, 2026 /PRNewswire/ -- DICK'S Sporting Goods, Inc. (NYSE:DKS) will announce results for the fourth quarter and full year 2025 before the market opens on Thursday, March 12th.      A conference call to discuss the results will be held that day at 10:00 a.m. Eastern Time. The call is being webcast and can be accessed at DICK'S Sporting Goods' Investor Relations website at investors.dicks.com. To listen to the live call, please go to the website at least fifteen minutes early to register and download and install any necessary audio software. A playback of the ca

    2/6/26 8:00:00 AM ET
    $DKS
    Other Specialty Stores
    Consumer Discretionary

    $DFLI
    $DKS
    $FN
    $FRBK
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Dragonfly Energy Holdings Corp.

    SCHEDULE 13G - Dragonfly Energy Holdings Corp. (0001847986) (Subject)

    2/17/26 4:35:55 PM ET
    $DFLI
    Industrial Machinery/Components
    Miscellaneous

    Amendment: SEC Form SCHEDULE 13G/A filed by Fulcrum Therapeutics Inc.

    SCHEDULE 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)

    2/17/26 4:29:29 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by ProMIS Neurosciences Inc.

    SCHEDULE 13G/A - ProMIS Neurosciences Inc. (0001374339) (Subject)

    2/17/26 4:24:30 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DFLI
    $DKS
    $FN
    $FRBK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Cashman Neil was granted 4,122 shares (SEC Form 4)

    4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

    2/5/26 8:41:16 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Development Officer Kaplan Johanne was granted 2,060 shares, increasing direct ownership by 817% to 2,312 units (SEC Form 4)

    4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

    2/5/26 8:40:29 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Warma Neil K was granted 6,183 shares (SEC Form 4)

    4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

    2/5/26 8:39:31 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DFLI
    $DKS
    $FN
    $FRBK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Abg Management Ltd. bought $8,499,988 worth of shares (700,741 units at $12.13) (SEC Form 4)

    4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

    2/5/26 7:00:01 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Principal Accounting Officer Milbury Max A. bought $14,929 worth of shares (30,392 units at $0.49), increasing direct ownership by 203% to 45,389 units (SEC Form 4)

    4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

    10/6/25 9:12:38 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Eddy Robert W. bought $501,053 worth of shares (2,637 units at $190.01), increasing direct ownership by 77% to 6,048 units (SEC Form 4)

    4 - DICK'S SPORTING GOODS, INC. (0001089063) (Issuer)

    6/27/25 5:01:01 PM ET
    $DKS
    Other Specialty Stores
    Consumer Discretionary

    $DFLI
    $DKS
    $FN
    $FRBK
    Leadership Updates

    Live Leadership Updates

    View All

    DICK'S Sporting Goods Names Matthew Barnes President, Foot Locker International

    PITTSBURGH, Nov. 25, 2025 /PRNewswire/ -- DICK'S Sporting Goods today announced the appointment of Matthew Barnes as President of Foot Locker International, effective December 3, 2025. Barnes will lead the Foot Locker business' international operations with a focus on driving strategic growth, accelerating business momentum and executing targeted turnaround strategies. In his position at Foot Locker, now part of DICK'S Sporting Goods following its acquisition in September 2025, Barnes will oversee the Foot Locker stores, eCommerce and digital businesses across Europe, Asia and

    11/25/25 2:00:00 AM ET
    $DKS
    Other Specialty Stores
    Consumer Discretionary

    ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group

    Appointment reinforces ProMIS Neurosciences' strategic vision and deepens investor engagement as the Company advances its differentiated Alzheimer's program, PMN310 Cambridge, Massachusetts, Oct. 22, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (NASDAQ:PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other neurodegenerative disorders, today announced that Slanix Paul Alex, Pharm.D., President and Portfolio Manager for Ally Bridge Group's Public Equity strategy, has joined the Company's Board of Directors. Dr. Alex has a highly distinguished Wall Street career spanning multiple leadership positions at public market

    10/22/25 7:30:00 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fabrinet Appoints Caroline Dowling to Board of Directors

    BANGKOK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Fabrinet (NYSE:FN), a leading provider of advanced optical packaging and precision optical, electro-mechanical and electronic manufacturing services to original equipment manufacturers of complex products, today announced that Caroline Dowling has been appointed to Fabrinet's Board of Directors. Ms. Dowling brings significant operational and leadership experience from a global manufacturing business and deep industry knowledge to the Board of Directors. Having spent more than 20 years at Flex, a top-tier electronic manufacturing services (EMS) provider, Ms. Dowling is a highly experienced business leader with extensive global expertise in the tec

    10/16/25 4:15:00 PM ET
    $CRH
    $FN
    Building Materials
    Industrials
    Telecommunications Equipment
    Utilities

    $DFLI
    $DKS
    $FN
    $FRBK
    Financials

    Live finance-specific insights

    View All

    Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

    CAMBRIDGE, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, will host a conference call and webcast on Tuesday, February 24, 2026 beginning at 8:00 a.m. ET to present 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease. Members of Fulcrum management will be joined by Dr. Martin Steinberg, Professor of Medicine, Pediatrics, Pathology and Laboratory Medicine at Boston University Chobanian and Avedisian School of Medicine. To register for

    2/17/26 8:00:00 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DICK'S Sporting Goods, Inc. Fourth Quarter Results Call Scheduled for March 12th

    PITTSBURGH, Feb. 6, 2026 /PRNewswire/ -- DICK'S Sporting Goods, Inc. (NYSE:DKS) will announce results for the fourth quarter and full year 2025 before the market opens on Thursday, March 12th.      A conference call to discuss the results will be held that day at 10:00 a.m. Eastern Time. The call is being webcast and can be accessed at DICK'S Sporting Goods' Investor Relations website at investors.dicks.com. To listen to the live call, please go to the website at least fifteen minutes early to register and download and install any necessary audio software. A playback of the ca

    2/6/26 8:00:00 AM ET
    $DKS
    Other Specialty Stores
    Consumer Discretionary

    Fabrinet Announces Second Quarter Fiscal Year 2026 Financial Results

    BANGKOK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Fabrinet (NYSE:FN), a leading provider of advanced optical packaging and precision optical, electro-mechanical and electronic manufacturing services to original equipment manufacturers of complex products, today announced its financial results for its second fiscal quarter ended December 26, 2025. Seamus Grady, Chairman and Chief Executive Officer of Fabrinet, said, "We delivered an exceptional second quarter with record revenue and earnings that significantly exceeded our guidance ranges. Multiple large, key strategic programs across our business all contributed to our outstanding performance. At the same time, excellent execution and strong ope

    2/2/26 4:15:00 PM ET
    $FN
    Telecommunications Equipment
    Utilities

    $DFLI
    $DKS
    $FN
    $FRBK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Dragonfly Energy Holdings Corp.

    SC 13D/A - Dragonfly Energy Holdings Corp. (0001847986) (Subject)

    11/21/24 6:10:38 PM ET
    $DFLI
    Industrial Machinery/Components
    Miscellaneous

    Amendment: SEC Form SC 13G/A filed by ProMIS Neurosciences Inc.

    SC 13G/A - ProMIS Neurosciences Inc. (0001374339) (Subject)

    11/14/24 4:56:13 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Fulcrum Therapeutics Inc.

    SC 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)

    11/14/24 4:25:46 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care